The interaction test revealed no significant effect differences across all subgroups stratified by eGFR; HbA1c; presence of hypertension, ischemic heart disease, heart failure, proteinuria, or diabetic complications; use of metformin, insulin, SGLT2is, ACEis, or ARBs; previous use of GLP-1 RAs; potential treatment indications (body weight loss, glycemic control, or both); LDL cholesterol level; or BMI (all interaction test P > .05) (eFigures 4-9 in Supplement 1). This evidence concerns the gene GLP1R and coronary artery disorder.